Back to search

Netherlands· NL-3ed071f98bca

GAMMAGARD S/D 10,0 g, poeder en oplosmiddel voor oplossing voor infusie

A humane immunglobuline, unspezifisch, intravaskulär product containing humaan, normaal immunoglobuline voor intraveneus gebruik, registered in Netherlands by Baxalta Innovations GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC J06BA02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedGAMMAGARD S/D 10,0 g, poeder en oplos…ATCJ06BA02REGISTER NO.NL-3ed071f98bcaPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Humane immunglobuline, unspezifisch, intravaskulär is registered in 11 of 19 countries.

Countries holding a registration under ATC J06BA02 (humane immunglobuline, unspezifisch, intravaskulär), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Humane immunglobuline, unspezifisch, intravaskulär · ATC J06BA02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
HUMAAN, NORMAAL IMMUNOGLOBULINE VOOR INTRAVENEUS GEBRUIK
Manufacturer
Baxalta Innovations GmbH
Country
Netherlands (NL)
ATC code
J06BA02
ATC class
Humane Immunglobuline, unspezifisch, intravaskulär
Defined daily dose
1.6 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    17034

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

48 interactions on record for humane immunglobuline, unspezifisch, intravaskulär.

Graded by severity as the source publishes them — 44 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Humane immunglobuline, unspezifisch, intravaskulär · interactions on record

48 records

  • 44 severe
  • 4 minor

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Amphotericin BA07AA07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Humane immunglobuline, unspezifisch, intravaskulär in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All humane immunglobuline, unspezifisch, intravaskulär products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Cutaquig, Cuvitru
  • Belgium · Cutaquig, Cuvitru
  • Bulgaria · Имуновенин, Интратект
  • Cyprus · Gamunex, Intratect
  • Czechia · Cutaquig, Cuvitru
  • Germany · Beriglobin, Cutaquig
  • Denmark · Cutaquig, Cuvitru
  • Estonia · Cutaquig, Gammanorm
  • Spain · Cutaquig, Cuvitru
  • Finland · Cutaquig, Cuvitru
  • France · Clairyg, Cutaquig
  • United Kingdom (Northern Ireland) · Cutaquig, Cuvitru
  • Greece · Gaminex, Ig Vena
  • Croatia · Cutaquig, Ig Vena
  • Hungary · Cutaquig, Gammanorm
  • Ireland · Cutaquig, Cuvitru
  • Iceland · Cutaquig, Deqsiga
  • Italy · Cutaquig, Cuvitru
  • Liechtenstein · Deqsiga, Flebogamma Dif
  • Lithuania · Cutaquig, Gammanorm
  • Luxembourg · Cutaquig, Gammagard S/D (Solvent/Detergent)
  • Latvia · Cutaquig, Gammanorm
  • Malta · Cutaquig, Gammanorm
  • Norway · Cutaquig, Cuvitru
  • Poland · Cutaquig, Cuvitru
  • Portugal · Cutaquig, Gammanorm
  • Romania · Cutaquig, Gammanorm
  • Sweden · Cutaquig, Cuvitru
  • Slovenia · Cutaquig, Gammanorm
  • Slovakia · Cutaquig, Cuvitru

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e3923ef2-9fad-4e4d-8980-57b0bd7a5b47
GET /v1/drugs/e3923ef2-9fad-4e4d-8980-57b0bd7a5b47?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder en oplosmiddel voor oplossing voor infusie",
  "route": null,
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h17034_smpc.pdf",
  "strength": null,
  "atc_label": "Immunoglobulins, Normal Human, For Intravascular Adm.",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg17034",
  "excipients": [
    "GLUCOSE 1-WATER",
    "GLYCINE (E 640)",
    "HUMAAN ALBUMINE",
    "NATRIUMCHLORIDE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "HUMAAN, NORMAAL IMMUNOGLOBULINE VOOR INTRAVENEUS GEBRUIK"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h17034.pdf",
  "authorised_at": "1994/07/07",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "17034",
  "additional_monitoring": "N"
}

See everything about humane immunglobuline, unspezifisch, intravaskulär.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.